The Relationship Between a Genetic Variant in the HSPB1 Gene and a Lower Risk of Cardiovascular Diseases: The Results of the MASHAD Cohort Study

Coronary heart disease (CHD) is a leading cause of death, highlighting the importance of risk stratification and prognostic biomarkers in CHD. There is a growing body of evidence supporting the potential value of heat shock proteins (HSPs) in the pathogenesis of atherosclerosis. Here, we explored the relationship between serum anti-HSP27 levels and a genetic variant, rs2868371, in the HSPB1 gene in the Stroke and Heart Atherosclerotic Disorders (MASHAD) cohort study carried out in Mashhad. A total of 8776 subjects were recruited. Anti-HSP27 levels were measured using an in-house enzyme-linked immunosorbent assay (ELISA), followed by genotyping using a TaqMan® probe-based assay. Demographic, biochemical, and hematological characteristics of the population were evaluated in all subjects. Kaplan-Meier curves were utilized, while logistic regression models were used to evaluate the relationship between genotypic frequencies and clinical characteristics of the population. No significant difference in anti-HSP27 levels was demonstrated between subjects with and without CHD. The frequencies of the CC, CG, and GG genotypes were 68%, 26.8%, and 5.2%, respectively. CAD patients with GG and GC genotypes had a lower risk of myocardial infarction (MI) compared with the reference group after adjusting for confounding factors [OR=0.27 (95% CI=0.08-0.94), P=0.040]. Our data revealed a relationship between the genetic variant in the HSPB1 gene and the risk of developing CHD, supporting further research on the potential value of this emerging marker in predicting

1. Baghianimoghadam MH, Mirzaei M, Rahimdel T. Role of health beliefs in preventive behaviors of individuals at risk of cardiovascular diseases. J Health Syst Res 2012;8:1151-8.
2. Sanchis-Gomar F, Perez-Quilis C, Leischik R, Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med 2016;4:256.
3. Lamb DJ, El-Sankary W, Ferns GA. Molecular mimicry in atherosclerosis: a role for heat shock proteins in immunisation. Atherosclerosis 2003;167:177-85.
4. Ghayour-Mobarhan M, New SA, Lamb DJ, Starkey BJ, Livingstone C, Wang T, et al. Dietary antioxidants and fat are associated with plasma antibody titers to heat shock proteins 60, 65, and 70 in subjects with dyslipidemia. Am J Clin Nutr 2005;81:998-1004.
5. Pourghadamyari H, Moohebati M, Parizadeh SMR, Falsoleiman H, Dehghani M, Fazlinezhad A, et al. Serum antibody titers against heat shock protein 27 are associated with the severity of coronary artery disease. Cell Stress Chaperones 2011;16:309-16.
6. Martin JL, Hickey E, Weber LA, Dillmann WH, Mestril R. Influence of phosphorylation and oligomerization on the protective role of the small heat shock protein 27 in rat adult cardiomyocytes. Gene Expr 2018;7:349-55.
7. Ghayour-Mobarhan M, Rahsepar A, Tavallaie S, Rahsepar S, Ferns G. The potential role of heat shock proteins in cardiovascular disease: evidence from in vitro and in vivo studies. Adv Clin Chem 2009;48:27-72.
8. Arata S, Hamaguchi S, Nose K. Effects of the overexpression of the small heat shock protein, HSP27, on the sensitivity of human fibroblast cells exposed to oxidative stress. J Cell Physiol 1995;163:458-65.
9. Park HK, Park EC, Bae SW, Park MY, Kim SW, Yoo HS, et al. Expression of heat shock protein 27 in human atherosclerotic plaques and increased plasma level of heat shock protein 27 in patients with acute coronary syndrome. Circulation 2006;114:886-93.
10. Guerra JLL, Wei Q, Yuan X, Gomez D, Liu Z, Zhuang Y, et al. Functional promoter rs2868371 variant of HSPB1 associates with radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with radio (chemo) therapy. Radiother Oncol 2011;101:271-7.
11. Ghayour-Mobarhan M, Moohebati M, Esmaily H, Ebrahimi M, Parizadeh SMR, Heidari-Bakavoli AR, et al. Mashhad stroke and heart atherosclerotic disorder (MASHAD) study: design, baseline characteristics and 10-year cardiovascular risk estimation. Int J Public Health 2015;60:561-72.
12. Tremblay AJ, Morrissette H, Gagné JM, Bergeron J, Gagné C, Couture P. Validation of the Friedewald formula for the determination of low-density lipoprotein cholesterol compared with β-quantification in a large population. Clin Biochem 2004;37:785-90.
13. Xu Q, Wick G, Willeit J, Marosi M, Kiechl S, Luef G, et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet 1993;341:255-9.
14. Ghayour-Mobarhan M, Lamb D, Lovell D, Livingstone C, Wang T, Ferns G. Plasma antibody titres to heat shock proteins-60,-65 and-70: Their relationship to coronary risk factors in dyslipidaemic patients and healthy individuals. Scand J Clin Lab Invest 2005;65:601-14.
15. Burt D, Bruno G, Chaturvedi N, Schalkwijk C, Stehouwer CD, Witte DR, et al. Anti–Heat Shock Protein 27 Antibody Levels and Diabetes Complications in the EURODIAB Study. Diabetes Care 2009;32:1269-71.
16. Burut DFP, Borai A, Livingstone C, Ferns G. Serum heat shock protein 27 antigen and antibody levels appear to be related to the macrovascular complications associated with insulin resistance: a pilot study. Cell Stress Chaperones 2010;15:379-86.
17. Shams S, Shafi S, Bodman-Smith K, Williams P, Mehta S, Ferns GA. Anti-heat shock protein-27 (Hsp-27) antibody levels in patients with chest pain: association with established cardiovascular risk factors. Clin Chim Acta 2008;395:42-6.
18. Rahsepar AA, Mirzaee A, Moodi F, Moohebati M, Tavallaie S, Khorashadizadeh F, et al. Changes in anti-heat shock protein 27 antibody and C-reactive protein levels following cardiac surgery and their association with cardiac function in patients with cardiovascular disease. Cell Stress Chaperones 2013;18:65-74.
19. Li X, Xu S, Cheng Y, Shu J. HSPB1 polymorphisms might be associated with radiation-induced damage risk in lung cancer patients treated with radiotherapy. Tumour Biol 2016;37:5743-9.
20. Xu T, Wei Q, Guerra JLL, Wang LE, Liu Z, Gomez D, et al. HSPB1 gene polymorphisms predict risk of mortality for US patients after radio (chemo) therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2012;84:e229-35.
21. Xu F, Han JC, Zhang YJ, Zhang YJ, Liu XC, Qi GB, et al. Associations of LIG4 and HSPB1 genetic polymorphisms with risk of radiation-induced lung injury in lung cancer patients treated with radiotherapy. Biomed Res Int 2015;2015:860373.
22. Guo H, Bai Y, Xu P, Hu Z, Liu L, Wang F, et al. Functional promoter-1271G>C variant of HSPB1 predicts lung cancer risk and survival. J Clin Oncol 2010;28:1928-35.

Files	XML PDF (445KB)
Issue	Vol 64 No 7 (2026)
Section	Original Articles
DOI	https://doi.org/10.18502/acta.v64i7.22418
Keywords
Anti-HSP27 antibody CHD HSPB1 gene polymorphism rs2868371

Rights and permissions
	This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

Sadabadi F, Saberi-Karimian M, Ghazizadeh H, Moohebati M, Esmaily H, Khorrami Mohebbseraj MS, Darroudi S, Asadi Z, Pasdar A, Sahebkar A, Heidari-Bakavoli A, Samadi S, Azarpazhooh MR, Ferns GA, Avan A, Ghayour-Mobarhan M. The Relationship Between a Genetic Variant in the HSPB1 Gene and a Lower Risk of Cardiovascular Diseases: The Results of the MASHAD Cohort Study. Acta Med Iran. 2026;64(7):428-434.

Vancouver

Download Citation